What changed from existing technology?
This study compared two treatments for patients at high risk of heart problems after having a stent placed. One treatment was just clopidogrel, and the other was clopidogrel plus aspirin for a longer time. The study looked at how well each treatment worked in preventing bad heart events.
This study is the first to compare clopidogrel monotherapy with extended dual antiplatelet therapy in high-risk patients after drug-eluting stent implantation, focusing on long-term outcomes beyond 12 months.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 3
rel or Dual Antiplatelet Therapy in High-Ischemic-Risk Patients. BackgroundThe effect of clopidogrel monotherapy as compared with extended dual antiplatelet t
Title ↗12 months after implantation of a drug-eluting stent remains uncertain in patients at high risk for recurrent ischemic events. MethodsIn this open-label
Abstract ↗OpenAlex author affiliations: Samsung (South Korea)
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This study may inform treatment decisions for high-risk patients after drug-eluting stent implantation, but further research is needed to confirm long-term benefits and risks.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.
Evidence and sources
View paper and author affiliations
Open original researchClopidogrel or Dual Antiplatelet Therapy in High-Ischemic-Risk PatientsNew England Journal of Medicine · Published 2026-08-29 ↗Author institutions and listed legal entities are separated; only verified exchange and ticker data is linked.